531167 Sigma-AldrichGSK-3 Inhibitor XXIX, CHIR98014 - CAS 252935-94-7 - Calbiochem
A cell-permeable, highly potent, ATP-competitive, reversible inhibitor of both GSK-3α and β (IC₅₀ = 650 and 580 pM, respectively).
More>> A cell-permeable, highly potent, ATP-competitive, reversible inhibitor of both GSK-3α and β (IC₅₀ = 650 and 580 pM, respectively). Less<<MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
同义词: N²-(2-(4-(2,4-Dichlorophenyl)-5-(1H-imidazol-1-yl)pyrimidin-2-ylamino)ethyl)-5-nitropyridine-2,6-diamine, N⁶-(2-((4-(2,4-Dichlorophenyl)-5-(1H-imidazol-1-yl)-2-pyrimidinyl)amino}ethyl)-3-nitro-2,6-pyridinediamine, CHIR-98014, CT-98014
Recommended Products
概述
Replacement Information |
---|
重要规格表
CAS # | Empirical Formula |
---|---|
252935-94-7 | C₂₀H₁₇Cl₂N₉O₂ |
价格及供货情况
产品目录编号 | 库存情况 | 包装 | 数量 / 包装 | 价格 | 数量 | |
---|---|---|---|---|---|---|
5.31167.0001 |
|
玻璃瓶 | 5 mg |
|
— |
Product Information | |
---|---|
CAS number | 252935-94-7 |
Form | Yellow powder |
Hill Formula | C₂₀H₁₇Cl₂N₉O₂ |
Chemical formula | C₂₀H₁₇Cl₂N₉O₂ |
Reversible | Y |
Quality Level | MQ100 |
Applications |
---|
Biological Information | |
---|---|
Primary Target | GSK-3 α & β |
Primary Target IC<sub>50</sub> | 650 and 580 pM for GSK-3&alpha |
Primary Target K<sub>i</sub> | 870 pM for human GSK-3&beta |
Purity | ≥95% by HPLC |
Physicochemical Information | |
---|---|
Cell permeable | Y |
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Product Usage Statements |
---|
Packaging Information | |
---|---|
Packaged under inert gas | Packaged under inert gas |
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Global Trade Item Number | |
---|---|
产品目录编号 | GTIN |
5.31167.0001 | 04055977283150 |
Documentation
GSK-3 Inhibitor XXIX, CHIR98014 - CAS 252935-94-7 - Calbiochem MSDS
职位 |
---|
参考
参考信息概述 |
---|
Grigoryan, T., et al. 2013. Proc. Natl. Acad. Sci. USA 110, 18174. Lian, X., et al. 2012. Proc. Natl. Acad. Sci. USA 109, E1848. Selenica, M.L., et al. 2007. Br. J. Pharmacol. 152, 959. Ring, D.B., et al. 2003. Diabetes. 52, 588. Nikoulina, S.E., et al. 2002. Diabetes. 51, 2190. |
技术信息
标题 |
---|
Characterization of Estrogen Receptor α Phosphorylation Sites in Breast Cancer Tissue Using the SNAP i.d® 2.0 System |
White Paper: Further considerations of antibody validation and usage. |